Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009151165 - RECOMBINANT SARS-C O V N S P 12 AND THE USE THEREOF, AND THE METHOD FOR PRODUCING IT

Publication Number WO/2009/151165
Publication Date 17.12.2009
International Application No. PCT/KR2008/003333
International Filing Date 13.06.2008
IPC
C12N 15/50 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
C12N 15/33 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
G01N 2333/165
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
G01N 2333/9125
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
90Enzymes; Proenzymes
91Transferases (2.)
912transferring phosphorus containing groups, e.g. kinases (2.7)
91205Phosphotransferases in general
91245Nucleotidyltransferases (2.7.7)
9125with a definite EC number (2.7.7.-)
G01N 2500/04
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Applicants
  • INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY [KR]/[KR] (AllExceptUS)
  • KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION [KR]/[KR] (AllExceptUS)
  • OH, Jong Won [KR]/[KR] (UsOnly)
  • AHN, Dae Gyun [KR]/[KR] (UsOnly)
Inventors
  • OH, Jong Won
  • AHN, Dae Gyun
Agents
  • DANA PATENT LAW FIRM
Priority Data
Publication Language English (EN)
Filing Language Korean (KO)
Designated States
Title
(EN) RECOMBINANT SARS-C O V N S P 12 AND THE USE THEREOF, AND THE METHOD FOR PRODUCING IT
(FR) NSP 12 RECOMBINANTE DU SARS-COV, SON UTILISATION ET SON PROCÉDÉ DE PRODUCTION
Abstract
(EN)
The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp 12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nspl2. SARS-CoV nspl2 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp 12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp 12 were found.
(FR)
La présente invention concerne une protéine non structurelle (nsp) 12 recombinante du coronavirus du syndrome de détresse respiratoire aiguë sévère (SARS-CoV) avec une activité ARN polymérase, son vecteur d’expression, son procédé de préparation et son utilisation. Selon la présente invention, une nsp 12 recombinante soluble du SARS-CoV, avec une activité RdRp d’initiation de la synthèse du génome du SARS-CoV, peut être surexprimée dans les cellules hôtes transformées, et purifiée de manière appropriée avec une pureté élevée. Un système de réplication in vitro, important pour l’étude de la réplication du SARS-CoV, peut être mis en place avec la nsp12 recombinante purifiée du SARS-CoV. La nsp 12 du SARS-CoV produite par la présente invention peut aussi être utilisée en tant que cible pour le développement d’agents antiviraux contre le SARS-CoV. En outre, la présente invention permet de cribler efficacement des matériaux inhibant l’activité ARN polymérase ARN-dépendante (RdRp) de la nsp 12, puisque les conditions optimales pour le dosage de la RdRp avec la nsp 12 du SARS-CoV ont été découvertes.
Also published as
Latest bibliographic data on file with the International Bureau